top of page

Spun out of Paragon, Oruka Therapeutics raised $275M today as part of a reverse merger to tackle skin conditions in the I&I space

CEO Lawrence Klein describes advances in antibody engineering Oruka is leveraing to make improved IL-23 and IL-17 inhibitors.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page